Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.

@article{Beier2007SafetyTA,
  title={Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.},
  author={J. Beier and Pascal Chanez and Jean-Beno{\^i}t Martinot and Ad J. M. Schreurs and Ruzena Tkacova and Weibin Bao and Damon Jack and Mark N Higgins},
  journal={Pulmonary pharmacology & therapeutics},
  year={2007},
  volume={20 6},
  pages={740-9}
}
In patients with chronic obstructive pulmonary disease (COPD) classified as moderate onwards, Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines recommend regular treatment with one or more long-acting bronchodilators, such as beta(2)-agonists or anticholinergics. In contrast to currently available long-acting beta(2)-agonists, which have a duration of action of 12 h, indacaterol has demonstrated effective 24-h bronchodilation on once-daily dosing. A double-blind… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 24 extracted citations

Systematic review comparing LABA, olodaterol, and indacaterol: limitations

International journal of chronic obstructive pulmonary disease • 2014

Similar Papers

Loading similar papers…